Clinical Utility of Pegasparagase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

Cynthia Bender1
Luke Maese2
Maria Carter-Febres2
Anupam Verma1,2

1Department of Pharmacy, Primary Children’s Hospital, Salt Lake City, UT, USA; 2Division of Hematology/Oncology, Department of Pediatrics, University of Utah and Primary Children’s Hospital, Salt Lake City, UT, USA

Abstract: Acute lymphoblastic leukemia (ALL) is a heterogenous hematological malignancy representing 25% of all cancers in children less than 15 years of age. Significant improvements in survival and cure rates have been made over the past four decades in pediatric ALL treatment. Asparaginases, derived from Escherichia coli and Erwinia chrysanthemi, have become a critical component of ALL therapy since the 1960s. Asparaginases cause depletion of serum asparagine, leading to deprivation of this critical amino acid for protein synthesis, and hence limit survival of lymphoblasts. Pegasparagase, a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase, has become an integral component of pediatric upfront and relapsed ALL protocols due to its longer half-life and improved immunogenicity profile compared to native asparaginase preparations. Over the past two decades great strides have been made in outcomes for pediatric ALL due to risk stratification, incorporation of multiagent chemotherapy protocols, and central nervous system prophylaxis with pegasparagase having played an important role in this success. However, adolescents and young adults (AYA) with ALL when treated on contemporaneous trials using adult ALL regimens, continue to have poor outcomes. There is increasing realization of adapting pediatric trial regimens for treating AYAs, especially those incorporating higher intensity of chemotherapeutic agents with pegasparagase being one such agent. Dose or treatment-limiting toxicity is observed in 25–30% of patients, most notable being hypersensitivity reactions. Other toxicities include asparaginase-associated pancreatitis, thrombosis, liver dysfunction, osteonecrosis, and dyslipidemia. Discontinuation or subtherapeutic levels of asparaginase are associated with inferior disease-free survival leading to higher risk of relapse, and in cases of relapse, a higher risk for remission failure. This article provides an overview of available evidence for use of pegasparagase in pediatric acute lymphoblastic leukemia.

Keywords: asparagine, asparaginase, serum asparaginase activity, toxicity

Introduction

Acute lymphoblastic leukemia (ALL) is the most commonly encountered cancer of childhood with peak prevalence between ages 2–5 years. Two main subtypes, B-cell and T-cell, comprise the majority of ALL, at 85–90% and 10–15% of cases, respectively.1 Outcomes within pediatric ALL vary by subtype and risk category, but are generally favorable. While within standard-risk (SR) B-cell ALL overall survival (OS) is as high as 96%, high risk (HR) B-ALL and T-ALL...
continue to have lower event-free survival (EFS) and OS.2-6 Over the past several decades, significant progress has been made with risk stratification and chemotherapy dose intensification. Asparaginase, introduced as a component of the chemotherapeutic backbone for ALL in the 1970s, has been of significant importance in advancing the treatment of childhood leukemia.5,7,8 Its antileukemic activity is accomplished by converting asparagine to aspartic acid and ammonia in the extracellular fluid. Lymphoblasts are very sensitive to the lack of asparagine and this shortage reduces the synthesis of asparagine-dependent proteins causing cell death.9 There are extensive clinical data supporting the use and improved survival benefits of asparaginase therapy in pediatric ALL.2,3,10-17 Omission or low therapeutic levels of asparaginase may lead to higher risk of relapse, and in cases of relapse, a higher risk for remission failure.3,18-20 Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli (E. coli) derived L-asparaginase, is the preferred first-line asparaginase preparation in the multiagent chemotherapy regimens for treatment of childhood ALL in the United States (US) and European Union (EU).21-23 We provide an overview on the use of pegaspargase in pediatric ALL.

Pharmacological Characteristics of Pegaspargase

In comparison to healthy cells, leukemic cells have low levels of asparagine synthetase and hence, reduced ability to manufacture the essential amino acid asparagine needed for DNA, RNA and protein synthesis.24,25 Asparaginase hydrolyzes asparagine into aspartic acid and ammonia in the plasma, thus denying the lymphoblast an essential element needed for cell survival.26 Asparaginase was identified as a potential chemotherapeutic in 1961 when it was first isolated as an antilymphoma component of guinea pig serum.27 Studies in the 1960s used bacteria as alternate sources of asparaginase, leading to clinically available asparaginase derived from E. coli and Erwinia chrysanthemi.28,29

Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase produced endogenously by E. coli. These mPEG molecules increase solubility and stability of the protein conjugate in the plasma and prevent proteolytic cleavage of the enzyme, consequently increasing its half-life.22,30 They also provide an additional benefit of reduction in the risk of anaphylaxis and hypersensitivity reactions.

Dosage and Administration

Pegaspargase is supplied as a sterile, preservative-free solution in vials containing 3750 International Units (IU) of pegaspargase per 5 mL solution.21,22 The FDA-approved dose for pediatric leukemia is 2500 IU/m² given either intramuscularly (IM) or intravenously (IV) over 1-2 hours, not more often than every 14 days.21,22 Increased toxicity due to higher doses of pegaspargase is controversial. Lebovic et al reported a retrospective chart review of patients 1-21 years of age with B-ALL on pegaspargase and found that doses higher than 3750 IU were associated with higher rates of venous thromboembolism (VTE), pancreatitis, and hyperglycemia.31 Dose capping is frequently employed in the adult population, particularly in obese patients; however, it has not been standard practice in pediatrics and further studies should investigate the potential for toxicity in this subset of patients.

Pharmacokinetic (PK) Comparison Between IV and IM Administration

The goal of asparaginase therapy is to achieve complete asparagine depletion. Quantification of asparagine directly is biologically and logistically challenging, particularly in the clinical setting, so serum asparaginase activity (SAA) levels are accepted as the most reliable modality to measure asparaginase efficacy.32 While there has been recent debate regarding optimal SAA levels for adequate asparagine depletion, an SAA of >0.1 IU/mL is generally considered optimal.24,32-35 Both Children’s Cancer Group (CCG) 1962 and Children’s Oncology Group (COG) AALL07P4 studies have provided important PK data on IM and IV administration, respectively.24,34 After an IM dose of 2500 IU/m², the maximum concentration of asparaginase activity peaked at 1 IU/mL compared to 1.6 IU/mL for IV on day 5 with a half-life absorption estimated at 1.7 days.21,22,24 The replacement of native asparaginase with pegaspargase in the treatment of pediatric ALL has come about due to its prolonged terminal half-life. The average half-life is estimated at 5.5 days for both IM and IV administration and is 4-8
times longer than those of the native and Erwinia-derived products. Silverman et al also confirmed that enzyme activity is maintained for a minimum of 2 weeks after a single IV dose, thus supporting the recommendation that dosing not occur more frequently than 2-week intervals.

Comparison with Other Pegylated Products

Calaspargase (CALASP) was developed using the same asparaginase enzyme and PEG molecule as pegasparagase. However, whereas pegasparagase has a succinimidyl succinate (SS-PEG) molecule which combines the two, CALASP consists instead of a succinimidyl carbonate (SC-PEG) linkage which enables greater biologic stability. This stability is realized in the much longer shelf life of CALASP, 36 months, versus pegasparagase at 8 months. COG AALL07P4 investigated the PK and pharmacodynamic (PD) properties of calaspargase pegol (Asparlas). The results demonstrated a potential advantage to its use with CALASP having a more prolonged SAA compared with pegasparagase through both induction and consolidation. The mean half-life SAA was 2.5 times longer with CALASP than with pegasparagase, representing a more prolonged suppression of asparagine in the plasma. Although not statistically significant, adverse effects were similar between both groups other than CALASP had increased hyperglycemia in induction and hyperbilirubinemia in delayed intensification (DI).

Dana-Farber Cancer Institute (DFCI) 11–001 randomized patients to either pegasparagase every 2 weeks or CALASP every 3 weeks during intensification (Table 1). There were no significant differences in treatment outcomes or toxicities between the two arms, but PK data showed more prolonged SAA after CALASP in the induction phase. As the DFCI protocols have 3-week cycles during intensification, CALASP is an ideal fit for the asparagine depletion prescribed in their chemotherapeutic backbone. This new pegylated product, as well as the yet unproven pegylated Erwinia asparaginase (pegcrisantaspase), may offer future alternate treatment options to pegasparagase.

Table 1 Pediatric Acute Lymphoblastic Leukemia Trials with Pegasparagase Associated Objectives

| Cooperative Group/Study | Enrollment Period (N) | Asparaginase Objective(s) | Asparaginase Associated Findings |
|-------------------------|-----------------------|---------------------------|----------------------------------|
| **Upfront studies**     |                       |                           |                                  |
| DFCI 91–011            | 1991–1995 (377)       | ASP intensification PEG (IM) vs. L-asp (IM) | • Intensification improves outcomes  
• No significant difference in EFS with ASP preparation |
| CCG 196224             | 1997–1998 (187)       | PEG (IM) vs. L-asp (IM)  | • PEG: increased clearance of blasts, decreased antibodies |
| AIEOP ALL 200050       | 2002 (20)             | PEG (IV) as first line therapy | • Adequate SAA and ASN depletion |
| DFCI 05–00133          | 2005–2010 (463)       | PEG (IV) vs. L-asp (IM)  | • PEG: increased ASP course completion success and increased SAA  
• No significant difference in DFS with ASP preparation |
| COG AALL07P434,38      | 2008–2010 (166)       | PEG (IV) vs. CALASP (IV) | • CALASP: prolonged SAA |
| DFCI 11–00139          | 2012–2015 (230)       | PEG (IV) vs. CALASP (IV) | • CALASP: prolonged SAA |
| **Relapsed studies**   |                       |                           |                                  |
| CCG 194118             | 1995–1998 (93)        | PEG (IM) in relapse       | • Decreased ASN led to increased second remission |
| CHMC 100151            | 1997–2001 (28)        | PEG (IM) in relapse       | • Adequate SAA and ASN depletion |

Abbreviations: DFCI, Dana-Farber Cancer Institute; CCG, Children’s Cancer Group; AIEOP, Associazione Italiana di Ematologia e Oncologia Pediatrica; COG, Children’s Oncology Group; CHMC, Children’s Hospital and Regional Medical Center; PEG, pegasparagase; L-asp, L-asparaginase; CALASP, calaspargase; ASP, asparaginase; IM, intramuscular; IV, intravenous; EFS, event-free survival; DFS, disease-free survival; SAA, serum asparaginase activity level; ASN, asparagine.
Pegaspargase in Newly Diagnosed ALL

In the US there are different types of commercially available asparaginase formulations, an E. coli-derived pegylated asparaginase (pegaspargase) and an Erwinia derived asparaginase. The native E. coli derived L-asparaginase was removed from the US market by the manufacturer in 2012 but still plays an important historical role. The pegylated form of the drug, approved in 1994 for use in patients with ALL, increases the plasma retention time, decreases proteolysis and renal excretion, and protects from immune detection.

Standard Risk (SR) ALL

CCG 1962 was a randomized trial to evaluate safety, efficacy, and PK of a single IM dose of pegaspargase versus multiple IM doses of native E. coli asparaginase in each of 3 phases: a 4-week induction and 2, 8-week DI phases as part of a multiagent chemotherapeutic regimen. One hundred eighteen children in 8 CCG centers with SR ALL were enrolled between 1997–1998. Patients were randomly assigned to receive either 2500 IU/m² of pegaspargase IM on day 3 of induction and each DI phase, or 6000 IU/m² of native asparaginase IM 3 times per week for 9 doses in induction and 6 doses in each DI phase (Table 1). Patients assigned to the pegaspargase arm had significantly more rapid clearance of lymphoblasts from days 7 and 14 bone marrow aspirates (p ≤ 0.05). Twice (n = 16) as many patients in the native asparaginase arm had M3 bone marrow (>25% blasts) on day 7 than in the pegaspargase arm (n = 8). Four patients had M3 marrow on day 14, all were in the native asparaginase arm. The study postulated that the difference could be from more persistent, higher SAA in the pegaspargase patients. Half-lives of asparaginase were 5.5 days and 26 hours for pegaspargase and native asparaginase, respectively. Studies have shown when antibody titers are high, the asparaginase activity is often low. Low SAA in the native arm (26%) compared to the pegaspargase arm (2%) during the first DI phase established the primary endpoint of this study that incidence of high anti-asparaginase antibody titers in children treated with pegaspargase would be decreased by at least 50% in the first DI compared with those treated with native asparaginase. Three-year EFS was similar for both arms, 85% for pegaspargase and 78% for native asparaginase.

High Risk (HR) ALL

DCFI 91–01 protocol was designed to improve the outcome of children with newly diagnosed ALL while minimizing toxicity. Three hundred and seventy-seven patients (137 SR and 240 HR), aged 0–18 years, were enrolled between 1991–1995. Apart from substituting dexamethasone for prednisone, the duration of high dose asparaginase intensification was extended from 20 weeks (in prior protocols) to 30 weeks, and patients were randomized to receive either native or pegylated E. coli asparaginase (Table 1). Patients were administered either 2500 IU/m² pegaspargase IM every other week for 15 doses or 25,000 IU/m² native E. coli asparaginase IM every week for 30 doses during the intensification phase of therapy. Though the study did not find a significant difference in 5-year EFS based upon risk group (87% ± 3% for SR and 81% ± 3% for HR, p = 0.24), asparaginase intolerance (failure to receive at least 26 weeks of asparaginase) was an independent predictor of adverse outcome in multivariate analysis (p < 0.01). This finding suggested that the prolongation of asparaginase therapy may have contributed to the improved overall outcome of 5-year EFS (83% ± 2%) compared to previous protocols.
treatment (82 vs. 74%; p = 0.015). The median nadir SAA of ≥0.1 IU/mL was significantly higher in patients who received IV pegasparagase than in those who received IM native L-asparaginase (99 vs. 71%; p < 0.0001). Significantly more anxiety was reported by both patients and parent-proxy in the IM native L-asparaginase group than in the IV pegasparagase group (p ≤ 0.03). With a median follow-up of 6 years, 5-year EFS was 90% for IV pegasparagase versus 89% for IM native L-asparaginase (p = 0.58).

Pediatric Oncology Group (POG) study POG 8704 (T-3) established in 357 patients with T-ALL and 195 patients with advanced-stage T lymphoblastic lymphoma (LLY) that high dose asparaginase consolidation therapy improves survival in pediatric patients.

Associazione Italiana di Ematologia e Oncologia Pediatria (AIEOP) ALL 2000 protocol, utilizing an intensive multiagent Berlin-Frankfurt-Munster (BFM) chemotherapy backbone, studied the pharmacological effects of pegasparagase as the first-line product in children with ALL. Twenty patients with SR, intermediate-risk (IR), and HR ALL on the protocol were given 2 doses and 1 dose of pegasparagase during induction and reinduction phases, respectively (Table 1). The investigators studied the asparaginase depletion and clinical outcomes against a comparison cohort of 37 patients treated with the same chemotherapy schedule but with native asparaginase. This study demonstrated pegasparagase effectively substituted for the native asparaginase product in regard to serum activity levels and asparaginase depletion. Additionally, allergic reactions and immunologically mediated silent inactivation were drastically minimized despite multiple exposures to the drug.

Adolescents and Young Adults (AYA) ALL

Survival rates in AYA ALL are poor compared with those in younger children. Surveillance epidemiology and end results (SEER) data from 2000–2004 in ALL, reported a 10-year OS of 80% in children <15 years, falling to 60% in adolescents aged 15–20 years, and 30% in young adults aged 20–30 years. Multiple studies have looked at adopting pediatric protocols for AYA with improved overall outcomes. Asparaginase, as it does in younger children, plays an important role in AYA ALL therapy. Ram et al conducted a systematic review and meta-analysis of all comparative trials on AYA patients given chemotherapy with either pediatric-inspired regimens or conventional adult protocols, reviewing 11 trials and 2489 patients. AYA patients given pediatric inspired regimens had a statistically significant lower mortality rate at 3 years (RR 0.58; 95% CI 0.51–0.67), lower relapse rate (RR 0.51; 95% CI 0.39–0.66), superior CR (RR 1.05; 95% CI 1.01–1.10) and EFS (RR 1.66; 95% CI 1.39–1.99). The German Multicenter Study Group For Adult ALL (GMALL) protocols were originally based on pediatric BFM protocols and designed for AYA ALL. GMALL 07/03 enrolled 877 patients, utilized intensified shortened induction with dexamethasone rather than with prednisone, pegasparagase rather than native asparaginase in induction and consolidation, plus incorporated changes in the management of minimal residual disease with stem cell transplant. GMALL 07/03 had significant improvements in 5-year OS compared with previous protocol GMALL 05/93 (65% in GMALL 07/03 vs 46% in GMALL 05/93). A French study examined the outcomes of 177 AYAs aged 15–20 years comparing those who were treated on a pediatric inspired protocol FRALLE-93, or an adult protocol LALA-94A. FRALLE-93 showed significant better CR (98% v 81%; p = 0.002) and EFS (p = 0.0002) in B-ALL, and EFS (p = 0.05) in T-ALL. The cumulative doses of chemotherapies, most notably asparaginase, were higher in the pediatric protocol: 180,000 IU/m² in the pediatric regimen versus 9000 IU/m² in the adult regimen. Italian and Dutch retrospective studies compared outcomes in adolescents aged 14–18 years treated on pediatric AIEOP ALL 95 and 2000 protocols with those treated on the adult Gruppo Italiano per le Malattie Ematologiche dell’Adulto (GIMEMA) ALL 0496 and 2000 protocols, and Dutch Children’s Oncology Group (DCOG) pediatric regimen with the Hemato-Oncologie voor Volwassenen Nederland (HOVON) adult protocols in AYAs. Both comparisons showed improved outcomes in patients treated on pediatric protocols. The primary differences between the regimens were shorter intervals between courses (≤1 week versus ≤4 weeks) and more asparaginase (mean cumulative dosage: 101,000 IU/m² vs. 70,000 IU/m²) in the pediatric regimens.

Pediatric inspired regimens use higher doses of chemotherapeutic agents at shorter intervals, including pegasparagase, which have demonstrated superiority to conventional adult regimens in AYA ALL patients. Dosing scheme is not the only reason for improved outcomes as there are biological differences in AYAs that also play a role. Not only do AYAs have more toxicity to the intensive chemotherapies, they also have
Table 2 Standard Risk B-ALL Regimen (Adapted from Children’s Oncology Group AALL0932)

| Phase                        | Chemotherapy Agents          | Schedule                                                                 |
|------------------------------|------------------------------|--------------------------------------------------------------------------|
| Induction (35 days)          | Dexamethasone PO             | Days 1–28, 1, 8, 15, 22                                                  |
|                              | Vincristine IV               | Day 4                                                                    |
|                              | Pegaspargase IV              | Day 1 (CNS2 require more)                                                |
|                              | Cytarabine IT                | Days 8, 29                                                               |
|                              | Methotrexate IT              |                                                                          |
| Consolidation (28 days)      | Mercaptopurine PO            | Days 1–28                                                                |
|                              | Vincristine IV               | Day 1                                                                    |
|                              | Methotrexate IT              | Days 1, 8, 15                                                            |
| Interim Maintenance (IM 1)   | Vincristine IV               | Days 1, 11, 21, 31, 41                                                  |
| (56 days)                    | Methotrexate IV              | Days 1, 11, 21, 31, 41                                                  |
|                              | (escalating dose)            |                                                                          |
|                              | Methotrexate IT              | Day 31                                                                   |
| Delayed Intensification (56 days) | Dexamethasone PO           | Days 1–7 and 15–21                                                       |
|                              | Thioguanine PO               | Days 29–42                                                               |
|                              | Vincristine IV               | Days 1, 8, 15                                                            |
|                              | Doxorubicin IV               | Days 1, 8, 15                                                            |
|                              | Pegaspargase IV              | Day 4                                                                    |
|                              | Cyclophosphamide IV          | Days 29–32 and 36–39                                                     |
|                              | Cytarabine IT                | Days 1, 29                                                                |
|                              | Methotrexate IT              |                                                                          |
| Interim Maintenance (IM 2)   | Vincristine IV               | Days 1, 11, 21, 31, 41                                                  |
| (56 days)                    | Methotrexate IV              | Days 1, 11, 21, 31, 41                                                  |
|                              | (escalating dose)            |                                                                          |
|                              | Methotrexate IT              | Days 1, 31                                                                |
| Maintenance (12-week cycles for 2 years from IM 1) | Dexamethasone PO | Days 1–5, 29–33, and 57–61                                              |
|                              | Mercaptopurine PO            | Days 1–84                                                                |
|                              | Methotrexate PO              | Weekly starting Day 8                                                   |
|                              | Vincristine IV               | Days 1, 29, 57                                                          |
|                              | Methotrexate IT              | Day 1                                                                    |

Abbreviations: PO, oral; IV, intravenous; IT, intrathecal; CNS, central nervous system.

Table 3 High-Risk B and T-ALL Regimens (Adapted from Children’s Oncology Group AALL1131, AALL0431)

| Phase                        | Chemotherapy Agents            | Schedule                                                                 |
|------------------------------|--------------------------------|--------------------------------------------------------------------------|
| Induction (35 days)          | Dexamethasone PO (< 10 years of age)* | Days 1–14                                                                |
|                              | Prednisone PO (≥ 10 years of age)* | Days 1–28                                                                |
|                              | Vincristine IV                  | Days 1, 8, 15                                                            |
|                              | Daunorubicin IV                 | Days 1, 8, 15                                                            |
|                              | Pegaspargase IM/IV              | Day 4                                                                    |
|                              | Cytarabine IT                   | Day 1 (B-ALL CNS2 require more)                                         |
|                              | Methotrexate IT                 | Days 8, 29 (also Days 15, 22 for CNS3)                                   |
| Consolidation (56 days for B-ALL: 77 days for T-ALL) | Mercaptopurine PO | B-ALL: Days 1–14 and 29–42                                               |
|                              | Cyclophosphamide IV             | T-ALL: Days 8–21 and 50–63                                               |
|                              | Cytarabine IV                   | T-ALL: Days 1, 29                                                        |
|                              | Pegaspargase IM/IV              | T-ALL: Days 8, 50                                                        |
|                              | Methotrexate IT                 | T-ALL: Days 1, 15, 22                                                     |
|                              | T-ALL: Days 15, 22, 64          | (CNS3 omit d22)                                                          |
| Interim Maintenance (IM) 36 | Mercaptopurine PO              | B-ALL only: Days 1–56                                                    |
| (63 days for B-ALL; 56 days for T-ALL) | Vincristine IV                 | B-ALL: Days 1, 15, 29, 43                                                 |
|                              | High Dose                      | T-ALL: Days 1, 11, 21, 31, 41                                            |
|                              | Methotrexate IV                 | T-ALL: only: Days 1, 15, 29, 43                                           |
|                              | Escalating Dose                | T-ALL: Days 1, 1, 21, 31, 41                                             |
|                              | Methotrexite IT                 | T-ALL: Days 1, 29                                                        |
|                              | Methotrexite IT                 | T-ALL: Days 1, 31                                                        |
|                              | Pegaspargase IV/IM              | T-ALL: Days 2, 22                                                        |
| Delayed Intensification (56 days for B-ALL: 63 days for T-ALL) | Dexamethasone PO | Days 1–7 and 15–21                                                       |
|                              | Thioguanine PO                  | B-ALL: Days 29–42                                                        |
|                              | Vincristine IV                  | T-ALL: Days 36–49                                                        |
|                              | Doxorubicin IV                  | Days 1, 8, 15, 43, 50 (T-ALL omit d43)                                   |
|                              | Pegaspargase IM/IV              | Days 1, 8, 15                                                            |
|                              | Cytarabine IV                   | B-ALL: Days 4, 43                                                        |
|                              | Methotrexite IT                 | T-ALL: Days 4, 50                                                        |
|                              | Methotrexite IT                 | Day 29                                                                   |
|                              | Pegaspargase IV/IM              | Days 29–32 and 36–39                                                     |
|                              | Cytarabine IV                   | Days 1, 29, 36 (T-ALL d29 given on d43)                                  |

(Continued)

reduced prevalence of genetic subtypes associated with favorable outcome and simultaneously an increase in subtypes associated with poor outcome. There is near-universal consensus from prior studies supporting the use of pegaspargase as the front-line asparaginase product in children and AYAs with newly diagnosed ALL (Tables 2 and 3).

Relapsed ALL
Apart from becoming an integral component of therapy regimens for first-line treatment of pediatric ALL, pegaspargase has also established a critical role in
treatment regimens for relapsed ALL. CHMC 1001 enrolled 28 pediatric patients with relapsed ALL at 3 pediatric institutions to study PK after pegaspargase therapy.52 Patients received induction therapy (including pegaspargase 2500 IU/m<sup>2</sup> IM weekly on days 2, 9, 16, and 23) and intensification therapy (including pegaspargase 2500 IU/m<sup>2</sup> IM once on day 7) (Table 1). Adequate serum and CSF asparagine depletion with SAA of >0.1 IU/mL was observed and maintained during induction and intensification in the majority of samples. CCG 1941 utilized 2 doses of pegaspargase on days 2 and 16, in combination with multiagent chemotherapy during re-induction, to explore possible relationships among SAA, asparagine depletion, anti-asparaginase antibody titers, and response to re-induction therapy in children and adolescents with early first bone marrow ALL relapse (Table 1).18 The study enrolled 214 patients between 1995–1998. The difference in asparaginase levels between M1 and M3 response at end of re-induction was statistically significant (p = 0.01). Lesser asparagine depletion was associated with failure to achieve second remissions.18 ALLR3 enrolled 216 patients aged 1–18 years in centers throughout Europe, Australia and New Zealand, on an open-label randomized trial for first ALL relapse, with a conventional four-drug induction and continuous asparaginase depletion throughout the first 3 months. ALLR3 has since become the standard chemotherapy regimen for many relapsed ALL re-induction protocols.53

| Table 3 (Continued). | Table 4 Relapse ALL Regimen (Adapted from UKALLR3) |
|---|---|
| Phase | Chemotherapy Agents | Schedule | Phase | Chemotherapy Agents | Schedule |
| Maintenance<sup>a</sup> (12-week cycles for 2 years from IM) | Prednisone PO | Days 1–5, 29–33, and 57–61 | Induction (28 days) | Dexamethasone PO | Days 1–5, 15–19 |
| | Mercaptopurine PO | Days 1–84 | Vincristine IV | Days 3, 10, 17, 24 |
| | Methotrexate PO | Weekly starting Day 8 | Mitoxantrone IV | Days 1, 2 |
| | Vinca IV | Days 1, 29, 57 | Pegaspargase IM/IV | Days 3, 18 |
| | Methotrexate IT | B-ALL: Days 1, 29 (first 4 cycles only) | Methotrexate IT | Days 1, 8 (also Days 15, 22 for CNS3) |
| | T-ALL: Day 1 only | | Intensification (28 days) | Dexamethasone PO | Days 1–5 |
| | | | Vincristine IV | Day 3 |
| | | | Methotrexate IV | Day 8 |
| | | | Pegaspargase IM/IV | Day 8 |
| | | | Cyclophosphamide IV | Day 15–19 |
| | | | Etoposide IV | Day 15–19 |
| | | | Methotrexate IT | Day 8 |
| | | | | | |
| Before SCT | Fludarabine IV | Days 1–5 |
| | Cytarabine IV | Days 1–5 |
| | Liposomal Daunorubicin IV | Day 1 |
| Before Maintenance<sup>a</sup> (weeks 14–29) | Dexamethasone PO | Days 1–5, 57–61 |
| | Vincristine IV | Days 3, 59 |
| | 6-mercaptopurine PO | Days 1–42, 57–98 |
| | Methotrexate PO | Days 10, 17, 31, 38, 67, 74, 88, 95 |
| | Etoposide IV | Days 42, 49, 99, 106 |
| | Cyclophosphamide IV | Days 42, 49, 99, 106 |
| | Cytarabine IV | Days 43–46, 50–53, 100–103, 107–110 |
| | Methotrexate IT | Days 1, 43, 57, 99 |
| Maintenance<sup>a</sup> (4-week cycles from weeks 30–104) | Dexamethasone PO | Days 1–5 |
| | Mercaptopurine PO | Days 1–28 |
| | Methotrexate PO | Weekly |
| | Vincristine IV | Day 1 |
| | Methotrexate IT | Day 1 |

Notes: *T-ALL patients receive prednisone only Days 1–28. **T-ALL patients receive nelarabine Days 1–5 and 43–47. ***T-ALL patients receive nelarabine on Days 29–33. **T-ALL patients receive an additional 3 cycles of nelarabine-based therapy prior to the start of maintenance (each cycle 84 days).

Abbreviations: PO, oral; IM, intramuscular; IV, intravenous; IT, intrathecal; CNS, central nervous system.

Pegaspargase is an important chemotherapy for treating pediatric ALL relapse and is included in the majority of US and European re-induction protocols with the ALLR3 or vincristine, dexamethasone, pegaspargase and doxorubicin (VXLD) inspired backbones (Tables 4 and 5).
Table 5 Relapse ALL Regimen* (Adapted from VXLD Re-Induction)

| Phase       | Chemotherapy Agents | Schedule                  |
|-------------|----------------------|---------------------------|
| Induction   |                      |                           |
| (28 days)   | Dexamethasone PO     | Days 1–14                 |
|             | Vincristine IV       | Days 1, 8, 15, 22         |
|             | Doxorubicin IV       | Day 1                     |
|             | Pegaspargase IM/IV   | Days 2, 16                |
|             | Methotrexate IT      | Day 1                     |
|             | Cytarabine IT        | Day 1                     |
| Consolidationa (28 days) | Dexamethasone PO | Days 1–5                  |
|             | Vincristine IV       | Day 3                     |
|             | Methotrexate IV      | Day 8                     |
|             | Pegaspargase IM/IV   | Day 9                     |
|             | Cyclophosphamide IV  | Days 15–19                |
|             | Etoposide IV         | Days 15–19                |
|             | Methotrexate IT      | Day 8                     |
| Consolidationb (56 days) | Mercaptopurine PO | Days 1–14 and 29–42       |
|             | Cyclophosphamide IV  | Days 1, 29                |
|             | Cytarabine IV        | Days 1–4, 8–11, 29–32,    |
|             |                      | and 36–39                 |
|             | Vincristine IV       | Days 15, 22, 43, 50       |
|             | Pegaspargase IM/IV   | Days 15, 43               |
|             | Methotrexate IT      | Days 1, 8, 15, 22         |

Notes: aRegimen used as backbone for relapsed ALL after window with novel agents eg, Bortezomib, Carfilzomib, Pevonedistat, Daratumumab, Blinatumomab, and Nivolumab. b Depending on study protocol. cConsolidation based on modified BFM.

Abbreviations: VXLD, vincristine, dexamethasone, pegaspargase, doxorubicin; PO, oral; IV, intravenous; IM, intramuscular; IT, intraheal.

Toxicity of Pegaspargase

In addition to its multiple clinical benefits, pegaspargase is notable for significant toxicity in up to 20–25% of all patients.54,55 These toxicities include hypersensitivity, pancreatitis, hyperglycemia, hyperlipidemia, liver dysfunction, hyperbilirubinemia, thrombosis, bleeding, and osteonecrosis (Figure 1).

Hypersensitivity to Pegaspargase

Allergic and infusion-related reactions in patients receiving asparaginase therapy are among the most common toxicities, ranging between 3–71% (Figure 1).56 Asparaginase hypersensitivity is mediated by antigen-specific IgG and/or IgE through the immunoglobulin receptors FcyRIII and FceRI, respectively.57 Hypersensitivity reactions to E. coli derived asparaginase, necessitate a switch to an alternative preparation such as Erwinia asparaginase.5,8,56,58 The incidence of hypersensitivity reactions depends on the number of prior exposures, interval between doses, type of asparaginase, use of premedication, and concomitant corticosteroid therapy. There are two types of true hypersensitivity reactions, antibody production with clinical manifestations and neutralizing antibody production reflected by a day 7 SAA below 0.1 IU/mL and/or a day 14 level below the lower limit of quantification with an absence of a clinical reaction, referred to as silent inactivation or subclinical hypersensitivity.32 The antibody formed to the naïve asparaginase or polyeethylene glycol portion of the pegaspargase alters the PK of the drug.59,60 The presence of these antibodies can inhibit asparaginase from depleting asparagine and ultimately decrease efficacy. Several studies suggest that pegaspargase is less immunogenic than the native E. coli formulation.3,60–62

The above referenced DFCI 91–01 study reported allergic reaction in 15% of patients; however, pegaspargase was associated with a lower incidence of allergic reactions (p = 0.02).3

The Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol enrolled 106 pediatric patients from 2008–2012. Six patients experienced a clinical allergic reaction to pegaspargase, a cumulative risk of 13.2%. Reactions usually occurred 2 hours after IM administration with symptoms ranging from mild to severe anaphylaxis.63 Additionally, NOPHO ALL2008, through a genome-wide association study (GWAS), correlated several genetic variants to an increased incidence of pegaspargase hypersensitivity.64

The Dutch Childhood Oncology Group (DCOG) ALL-10 study enrolled children ages 1–18 years with newly diagnosed ALL from 2009–2012.65 Patients were stratified into 3 risk groups after induction therapy (standard, medium and high) and all received 8 doses of native E. coli asparaginase (5000 IU/m² per dose) every 3 days in induction. Eighty-nine patients considered medium risk were given pegaspargase as first-line agent (2500 IU/m² per dose every other week) for a total of 15 doses during first 30 weeks of intensification. In the setting of allergy or silent inactivation, pegaspargase was replaced with Erwinia asparaginase. The investigators found a high incidence of inactivation of pegaspargase (22% clinical allergy and 8% silent inactivation) in the intensification phase due to antibody development against native E. coli asparaginase used in induction. They concluded that if a second pegaspargase course was administered, the allergy rate of pegaspargase would increase.65 DCOG ALL-11 study reported 14 allergic-like reactions or infusion reactions, 5 were to pegaspargase and 9 to Erwinia asparaginase. Allergic-like reactions occurred relatively late after the
start of infusion when compared to real allergies. They also were distinguished from real allergies by the absence of antibodies in all but one patient with an allergic-like reaction, while antibodies were detected in all patients with a real allergy. The study recommended if clinically tolerated, formulations should not be switched in case of allergic-like reactions.66

POG 8866 enrolled 76 patients <21 years with ALL in second bone marrow relapse from 1988–1992, with the aim of comparing efficacy and toxicity of pegaspargase to native E. coli asparaginase in the standard re-induction regimen.67 It was noted that all patients hypersensitive to native asparaginase tolerated at least 2 doses of pegaspargase given during induction phase. In those with known hypersensitivity to native asparaginase, increased clearance and decreased efficacy of pegaspargase were observed.67 Recently multiple studies have shown monitoring of ASNase activity ≥0.1 IU/mL, measured on days 7 and 14 post pegaspargase administration, during treatment of children with ALL is feasible and informative, demonstrating median trough PEG-ASNase activity being high in all patients without hypersensitivity.32,68,69

COG AALL1421 results suggest pre-existing anti-PEG antibodies with the increased use of pegylated products in food processing and cosmetics may also play a role in hypersensitivity reactions.40,41,70

Pegaspargase is a critical component of the chemotherapeutic backbone in upfront ALL protocols (Tables 2 and 3), and those patients who experience hypersensitivity to pegaspargase should discontinue any further dosing and switch to Erwinia asparaginase.71 However, during an Erwinia asparaginase shortage, Verma et al conducted a successful prospective study of pegaspargase desensitization in 10 patients with ALL/LLy who had experienced prior grade 3 or higher hypersensitivity reactions to either pegaspargase (6) or both pegaspargase and Erwinia asparaginase (4). A 13-step rapid desensitization protocol was utilized and SAA levels were measured between days 4–7 and days 10–14.72 Seven patients had sustained SAA activity, one achieved therapeutic levels but showed accelerated clearance, while two did not achieve adequate levels consistent with neutralizing antibodies. Although three of the 10 patients had mild to moderate hypersensitivity reactions, all were able to receive full protocol doses after clinical intervention. Others have since duplicated the safe administration of pegaspargase, while maintaining sustained SAA levels, utilizing a desensitization protocol in patients experiencing prior hypersensitivity reactions.72–74

An additional area of investigation for patients who experience hypersensitivity is the COG protocol AALL1931 (NCT04145531) an open-label, multicenter study for patients with ALL/LLy following hypersensitivity

---

| Toxicity       | Studies                                      |
|----------------|----------------------------------------------|
| Hypersensitivity | DFCI 91-01 3                                |
|                | NPOHC ALL2008 83                            |
|                | DCOG AL-10 85                               |
| Pancreatitis   | DFCI 87-01, 91-01, 95-01, 00-01 19           |
|                | UKALL 2003 32                               |
|                | NPOHC ALL2008 84                           |
| Hyperglycemia  | POG 9203 M 94                               |
| Hyperlipidemia | Total XV, XVI 95                            |
|                | DCOG AL-11 96                               |
| Hepatotoxicity | NPOHC ALL2008 86                            |
|                | DCOG AL-11 96                               |
| Thrombosis/    | DFCI 91-01, 95-01, 00-01, 05-01 86           |
| Bleeding       | COG 1962 96                                 |
|                | DCOG AL-10 92                               |
| Osteonecrosis  | Total XV 147                                |
|                | NPOHC ALL2008 89                            |
|                | CGC AALL33 118                              |

---

**Figure 1** Pegaspargase toxicity. *a* Due to lack of reported percentages for specific toxicities, hyperglycemia is not included.
to *E. coli* derived asparaginase with the objective to determine the efficacy, safety, and tolerability of IM recombinant crisantaspase *Pseudomonas fluorescens*.

**Pancreatitis**

Asparaginase-associated pancreatitis (AAP) was first reported in patients receiving the native L-asparaginase formulation. The origin, formulation, dosage and method of administration do not seem to influence the risk of pancreatitis.\(^7\) The exact pathophysiology of AAP is unknown, but it is believed to be caused by a systemic depletion of asparagine and thus reduction of protein synthesis. Organs with increased protein turnover such as the pancreas and liver are most at risk. Incidence of AAP is between 7–18% with it being more frequent in the AYA ALL population (Figure 1) and is one of the most common causes of truncation of asparaginase therapy, mostly due to the high chances of recurrence of AAP after rechallenge.\(^7\)\(^6\)\(^7\)\(^8\)

Kearney et al reviewed the clinical course of all children with ALL diagnosed with pancreatitis at DFCI from 1987–2003.\(^7\)\(^9\) A total of 1583 patients aged 0–18 years were enrolled in DFCI ALL consortium protocols (87–01, 91–01, 95–01, 00–01). Twenty-eight (7%) of 403 patients treated at Boston Children’s Hospital and 74 (6.4%) of 1155 patients in 10 other centers were diagnosed with at least one episode of AAP. Those patients with AAP had a higher median age, indicating patients 10–18 years of age have 2.4 times increased risk of developing pancreatitis. There was a non-statistically significant trend towards inferior 5-year EFS, with 29% of patients with history of AAP subsequently relapsing compared to only 14% without AAP.\(^7\)\(^9\) UKALL 2003 enrolled 3101 patients aged 1–25 years on 3 risk-stratified arms.\(^8\) SR and IR patients were exposed to a relatively small amount of pegaspargase (3000–4000 IU/m²) and HR patients received 12,000 IU/m². Pancreatitis was more common in asparaginase-containing blocks versus non-asparaginase containing blocks (83% vs. 17%; p < 0.0001). The median interval between receiving pegaspargase dose and developing AAP was 10 days. There was significant morbidity in the setting of AAP evidenced by increased readmission rates (29%), pseudocysts (25%), diabetes mellitus (13%), pleural effusions (8%), and renal failure (2%). Further pegaspargase was omitted in patients with higher grade AAP. The risk for pancreatitis was associated with increasing intensity of asparaginase treatment and dose, as well as increasing age.\(^8\)\(^0\) Similar results were observed by the NOPHO ALL2008 study with incidences of AAP higher in AYAs (10.1%) compared to in children (7%, p = 0.03) and 44% developed recurrence of AAP on rechallenge with asparaginase.\(^8\)\(^1\) An observational Ponti di Legno Toxicity Working Group reviewed patients on 26 trials conducted by 18 trial groups with children (1–18 years) between 1996–2016, to investigate the risk of complications and risk of re-exposing patients with AAP.\(^8\)\(^2\) Complications noted in the 465 patients with AAP included mechanical ventilation (8%), pseudocysts (26%), acute insulin need (21%), and death (2%). Older age was associated with more complications (10.5 years vs. 6.1 years without complications; p < 0.0001). One year after diagnosis of AAP, 11% of patients continued to need insulin, had recurrent abdominal pain, or both. Ninety-six patients were re-exposed to asparaginase, including 59 after severe AAP, and 44 (46%) patients developed a second episode, 22 (52%) being severe, suggesting a high risk of recurrence.\(^8\)\(^2\)

Patients with Common Terminology Criteria for Adverse Events (CTCAE) grade 1/2 AAP can be rechallenged after resolution, whereas it is recommended to omit further pegaspargase therapy in severe grades 3/4 AAP, as 44–63% have risk of recurrence on re-exposure.\(^7\)\(^5\)\(^7\)\(^9\)\(^8\)\(^1\)

**Hyperglycemia**

Pegaspargase-induced hyperglycemia is believed to be due to decreased insulin production and modification or deficiency of insulin receptors.\(^8\)\(^3\) The use of concomitant steroids and pegaspargase is believed to cause potentiation of hepatic gluconeogenesis and insulin resistance, thereby worsening hyperglycemia.\(^8\)\(^4\)\(^8\)

POG 9203 enrolled 34 patients between the ages of 1–21 years from 1992–1993. This study’s aims included feasibility determination of 29 biweekly doses of pegaspargase on a backbone of intensive multiagent antimetabolite consolidation and maintenance in HR B-ALL. Excessive toxicities attributed to pegaspargase and myelo-suppression were encountered during consolidation, causing the early closure of this study. Six patients developed hyperglycemia. The greatest risk factor appeared to be concomitant use of steroid therapy (Figure 1).\(^8\)\(^6\)

Although insulin therapy may be required in severe cases, severe hyperglycemia is usually transient and does not require truncation of pegaspargase therapy.\(^8\)\(^7\)
Hyperlipidemia
Asparaginase and steroids during ALL therapy lead to abnormalities in lipid metabolism, most notably resulting in hypertriglyceridemia and/or hypercholesterolemia. The exact mechanism for lipid dysregulation with asparaginase therapy is not known, but it is postulated to be due to an increase in the endogenous hepatic synthesis of very low-density lipoproteins. Another reason may be decreased activity in lipoprotein lipase, an enzyme involved in the removal of triglyceride-rich lipoproteins from the plasma. St. Jude Children’s Research Hospital evaluated different asparaginase formulations in patients ≤18 years of age with ALL on two trials; Total XV conducted from 2000–2007 and Total XVI from 2007–2017, enrolling 498 and 598 patients, respectively. SR/HR patients treated with pegaspargase had more severe hypertriglyceridemia compared to native L-asparaginase, and the highest increase occurred when pegaspargase was given in combination with dexamethasone. DCG ALL 10 reported 47% of patients receiving pegaspargase developed hypertriglyceridemia compared to 0% receiving Erwinia asparaginase, thereby suggesting prolonged exposure to asparaginase therapy was associated with hypertriglyceridemia (Figure 1).

Most patients have transient, asymptomatic hypertriglyceridemia. Omission or alteration of pegaspargase therapy is not recommended, though hypertriglyceridemia greater than 2000 mg/dL can enhance risk of AAP due to severe chylomicronemia. Preventive measures like dietary restrictions, fibrates, insulin infusions, heparin infusions, and plasmapheresis have been attempted, but their success in preventing AAP or other morbidities is not established.

Hepatotoxicity
Hepatic toxicities encountered with pegaspargase include direct damage to hepatocytes (elevated hepatic transaminases), cholestatic injury (elevated alkaline phosphatase and bilirubin), and impaired synthetic function (decreases in antithrombin, fibrinogen, and albumin with increases in cholesterol, phospholipids and triglycerides). The hepatotoxicity caused by asparaginase is believed to be due to abnormal mitochondrial function in the liver, alterations in lipoprotein metabolism, and secretion.

Though 75% patients had grade 1/2 elevation in bilirubin, sinusoidal obstructive syndrome (SOS) was noted in 27%, during NOPHO ALL2008 in patients undergoing maintenance treatment for ALL after the introduction of extended pegaspargase treatment. These findings prompted the hypothesis that pegaspargase in combination with other medications, such as mercaptopurine used during maintenance, might trigger SOS. DCOG ALL-11 study noted more patients developed grade 1–2 increases in ALT and AST (91%) during asparaginase with high dose methotrexate courses, but not grade 3–4 hepatotoxicity (9%) (Figure 1).

Most protocols do not recommend alteration in pegaspargase therapy due to hepatotoxicity, although this is another reason to consider dose capping in AYA patients. There are case reports of improvement in hepatic function with use of levcarnitine, a mitochondrial co-factor and vitamin B therapy.

Thrombosis and Bleeding
Asparaginase has simultaneous effects on procoagulant and thrombolytic proteins causing an increase in both thrombosis and bleeding. Asparaginase-induced depletion of asparagine in the serum leads to decreased synthesis of fibrinogen, plasminogen, anti-coagulation factor antithrombin III (ATIII), protein C, and protein S leading to increased thrombin formation. Additional factors contributing to the risk include concomitant steroid therapy particularly prednisone, indwelling central venous catheter, genetic thrombophilia, and underlying ALL itself.

DFCI studied 501 patients between 1991–2008 with newly diagnosed ALL. These patients were enrolled in four pediatric ALL protocols (91–01, 95–01, 00–01, and 05–01) and adult protocol 01–175. Five percent of pediatric patients and 34% of adult patients experienced thrombosis during treatment (Figure 1). The risk of thrombosis was noted to increase with age, with further risk stratification indicating a high risk for those >10 years of age and extremely high risk for those >30 years of age. CCG 1962 studied efficacy and PK of a single IM dose of pegaspargase instead of multiple IM doses of native E. coli asparaginase in 3 phases of SR ALL therapy. An incidence of cerebral venous sinus thrombosis (CVST) of 2–3% was observed for both regimens. DCOG ALL-10 enrolled 778 ALL patients between 2004–2013 and demonstrated VTE in 7.6% of patients with CVST in 44.1% of these VTE patients.

Patients with non-catheter-associated VTE should have asparaginase therapy withheld until imaging shows VTE and
CVST resolution. Patients should be treated with anticoagulation, preferably low-molecular-weight heparin, and upon resolution or stabilization of thrombus, consideration may be given to rechallenging with pegaspargase.\textsuperscript{100,101}

\textbf{Osteonecrosis}

Osteonecrosis is a known complication in 15–45\% of patients, especially AYA patients, undergoing treatment for ALL.\textsuperscript{103,104} Glucocorticoids, notably dexamethasone, are believed to induce inhibition of angiogenesis, bone marrow adipogenesis, hypercoagulation, and apoptosis of endothelial cells and osteocytes.\textsuperscript{105} Asparaginase decreases the clearance of dexamethasone due to its hypoproteinemia effect. Additionally, the immunosuppressive effects of glucocorticoids inhibit the antibody response against asparaginase and prevent a neutralizing effect causing higher SAA.\textsuperscript{105} The potentiated effect of asparaginase on glucocorticoid-induced osteonecrosis is believed to be in the setting of a hypercoagulable state which can lead to impaired circulation, vascular damage, and subsequent osteonecrosis.\textsuperscript{106}

Liu et al were the first to study the effects of asparaginase treatment on dexamethasone-induced osteonecrosis utilizing a mouse model.\textsuperscript{105} St. Jude’s Total XV protocol noted that patients with antibodies against asparaginase had a lower risk of developing osteonecrosis than those without the antibodies.\textsuperscript{107}

Osteonecrosis 5-year cumulative incidence (CI) was 6.3\% on NOPHO ALL2008 and the patients in the experimental arm who did not receive pegaspargase during dexamethasone containing DI had reduced frequency of osteonecrosis (Figure 1).\textsuperscript{108} NOPHO ALL2008 also correlated hyperlipidemia with osteonecrosis.\textsuperscript{109} Prolonged hyperlipidemia was associated with a significantly higher osteonecrosis specific hazard ratio (HR) per mmol/L for hypertriglyceridemia (HR=1.08, p=0.038) as well as for cholesterol levels (HR=1.26, p=0.039), and a tendency towards an inverse association with higher HDL (HR=0.22, p=0.053).\textsuperscript{109} The COG AALL0331 SR trial enrolled 5261 patients between 2005–2010.\textsuperscript{110} Osteonecrosis 5-year overall CI was 2.7\%. Extended exposure to pegaspargase was a likely contributing factor, possibly by potentiating dexamethasone exposure during DI. The study concluded the risk for osteonecrosis can be significantly reduced by using alternate week dexamethasone during DI, which is now standard on all COG ALL protocols.\textsuperscript{110}

Further studies are needed to elucidate whether lowering triglycerides and cholesterol during combined pegaspargase and dexamethasone therapy can reduce the risk of osteonecrosis.

\textbf{Conclusion}

Pegaspargase is an essential chemotherapeutic agent in all newly diagnosed pediatric and AYA ALL protocols, as well as most re-induction protocols for relapsed ALL. It is imperative to be aware of its toxicities and their management, so as to improve survival and decrease long-term morbidities in pediatric and AYA ALL. Areas of focus for future research should include asparaginase PK/PD of newer preparations, dosing regimens, interventions to mitigate toxicity, and role of genetics as it relates to asparaginase dosing and toxicity.

\textbf{Disclosure}

Anupam Verma, Cynthia Bender and Maria Carter have no conflicts of interest to report in this work. Luke Maese has served as consultant and has received honoraria from Jazz Pharmaceuticals.

\textbf{References}

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. \textit{Lancet}. 2008;371(9617):1030–1043. doi:10.1016/S0140-6736(08)60457-2
2. Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber cancer institute ALL consortium protocols for children with newly diagnosed acute lymphoblastic leukaemia (1985–2000). \textit{Leukemia}. 2010;24(2):320–334. doi:10.1038/lei.2009.253
3. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukaemia: results of Dana-Farber consortium protocol 91-01. \textit{Blood}. 2001;97(5):1211–1218. doi:10.1182/blood.v97.5.1211
4. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukaemia: results of total therapy study XIIIB at St Jude children’s research hospital. \textit{Blood}. 2004;104(9):2690–2696. doi:10.1182/blood-2004-04-1616
5. Brown P, Inaba H, Amesley C, et al. Pediatric acute lymphoblastic leukaemia, version 2.2020, NCCN clinical practice guidelines in Oncology. \textit{J Natl Compr Canc Netw}. 2020;18(1):81–112. doi:10.6004/jnccn.2020.0001
6. Mattano LA, Devidas M, Friedmann AM, et al. Outstanding outcome for children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: results of Children’s Oncology Group (COG) Study AALL0331. \textit{Blood}. 2014;124(21):793. doi:10.1182/blood.V124.21.793.793
7. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady J, Frei E 3rd, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukaemia. \textit{Cancer Res}. 1983;43(11):5601–5607.
8. Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukaemia. \textit{J Pharmacol Pharmacother}. 2016;7(2):62–71. doi:10.4103/0976-500X.184769
9. Kawedia JD, Ryting ME. Asparaginase in acute lymphoblastic leukaemia. \textit{Clin Lymphoma Myeloma Leuk}. 2014;14(Suppl):S14–S17. doi:10.1016/j.clml.2014.06.017
10. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. *N Engl J Med*. 2009;360(26):2730–2741. doi:10.1056/NEJMoa0900386
11. Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. *Hematol Oncol Clin North Am*. 2010;24(1):1–18. doi:10.1016/j.hoc.2009.11.014
12. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. *N Engl J Med*. 1996;335(11):657–663. doi:10.1056/NEJM19960913351101
13. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. *Leukemia*. 1999;13(3):335–342. doi:10.1038/sj.leu.2401310
14. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukaemia Group Phase 3 trial. *Blood*. 2002;99(8):2734–2739. doi:10.1182/blood.v99.8.2734
15. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. *J Clin Oncol*. 2005;23(28):7161–7167. doi:10.1200/jco.2005.11.411
16. Hefazi M, Litzow MR. Recent advances in the biology and treatment of T cell acute lymphoblastic leukemia. *Curr Hematol Malig Rep*. 2018;13(6):265–274. doi:10.1007/s11999-018-0455-9
17. Schrappe M, Möhrke A, Reiter A, et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. *Klin Padiatr*. 2013;225(Suppl S 01):S62–S70. doi:10.1055/s-0033-1337966
18. Jarrar M, Gaynor PS, Periclou AP, et al. Asparaginase depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children’s Oncology Group study (CCG-1941). *Pediatr Blood Cancer*. 2006;47(2):141–146. doi:10.1002/pbc.20713
19. Avramis VI, Tiwari PN. Asparaginase (native ASNAse or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. *Int J Nanomedicine*. 2006;1(3):241–254.
20. Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children’s Oncology Group. *J Clin Oncol*. 2020;38(17):1897–1905. doi:10.1200/JCO.19.03024
21. European Medicines Agency. Oncaspar (pegaspargase): summary of product characteristics. 2018. Available from: http://www.ema.europa.eu/. Accessed March 15, 2021
22. Shire Pharmaceuticals. Oncaspar (pegaspargase): US prescribing information. 2019. Available from: http://www.fda.gov. Accessed March 15, 2021.
23. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). *Oncologist*. 2007;12(8):991–998. doi:10.1634/theoncologist.12-8-991
24. Avramis V, Sencer S, Periclou A, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. *Blood*. 2002;99:1986–1994. doi:10.1182/blood.V99.6.1986
25. Heo YA, Syed YY, Keam SJ. Pegaspargase: a review in acute lymphoblastic leukemia. *Drugs*. 2019;79(7):767–777. doi:10.1007/s40265-019-01120-1
26. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. *Adv Exp Med Biol*. 1999;457:621–629.
27. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. *J Exp Med*. 1963;118(1):99–120. doi:10.1084/jem.118.1.99
28. Schwartz JH, Reeves JY, Broome JD. Two L-asparaginases from E. coli and their action against tumors. *Proc Natl Acad Sci U S A*. 1966;56(5):1516–1519. doi:10.1073/pnas.56.5.1516
29. Boyse EA, Old LJ, Campbell HA, Mashburn LT. Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase. *J Exp Med*. 1967;125(1):17–31. doi:10.1084/jem.125.1.17
30. Meneguetti GP, Santos JHPM, Obreque KMT, et al. Novel site-specific PEGylated L-asparaginase. *PLoS One*. 2019;14(2):e0219151. doi:10.1371/journal.pone.0219151
31. Lebovic R, Pearce N, Lacey L, Xenakis J, Faircloth CB, Thompson P. Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3750 IU. *Pediatr Blood Cancer*. 2017;64(10):e26555. doi:10.1002/pbc.26555
32. van der Sluis IM, Vroon LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. *Haematologica*. 2016;101(3):279–285. doi:10.3324/haematol.2015.137380
33. Place AE, Stevenson KE, Vroon LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. *Lancet Oncol*. 2015;16(16):1677–1690. doi:10.1016/S1470-2045(15)00363-0
34. Schore RJ, Devidas M, Bleyer A, et al. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children’s Oncology Group AALL07P4. *Leuk Lymphoma*. 2019;60(7):1740–1748. doi:10.1080/10428194.2018.1542146
35. Vroon LM, Blonquist TM, Supko JG, et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukaemia/lymphoma: results of DFCI 11-001. *J Clin Oncol*. 2019;37(15_suppl):10006. doi:10.1200/JCO.2019.37.15_suppl.10006
36. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. *Clin Pharmacokinet.* 2005;44(4):367–393. doi:10.2165/00003088-20054404-00003
37. Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. *Blood*. 2010;115(7):1351–1353. doi:10.1182/blood-2009-09-245951
38. Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children’s Oncology Group Study AALL07P4. *J Clin Oncol*. 2014;32(34):3874–3882. doi:10.1200/JCO.2014.55.5763
39. Lew G. Space for calaspargase? A new asparaginase for acute lymphoblastic leukemia. *Clin Cancer Res*. 2020;26(2):325–327. doi:10.1158/1078-0432.CCR-19-2975
40. Pui C-H, Liu Y, Relling MV. How to solve the problem of hypersensitivity to asparaginase? *Pediatr Blood Cancer*. 2018;65(3):e26884. doi:10.1002/pbc.26884
41. Rau RE, Dreyer Z, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, peginterasparaginase: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2018;65(3):26873. doi:10.1002/pbc.26873
42. Zalewska-Szewczyk B, Andrzejkowski W, Mlynarski W, Jedrychowska-Daisa K, Witas H, Bodalski J. The anti-asparaginase antibodies correlate with L-asparaginase activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48(5):931–936. doi:10.1080/10428190701292094
43. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91(1):24–31.
44. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646–1654. doi:10.1182/blood-2008-01-130237
45. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408–1411. doi:10.1182/blood-2008-06-164863
46. Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpillar O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimen: systematic review and meta-analysis. Am J Hematol. 2012;87(5):472–478. doi:10.1002/ajh.23149
47. Gökkübre N, Beck J, Brandt K, et al. Significant Improvement of outcome in Adolescents and Young adults (AYAs) aged 15-35 years with Acute Lymphoblastic Leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group For Adult ALL (GMALL). Blood. 2013;122(21):E839.
48. Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents and young adults with acute lymphoblastic leukemia be treated as children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774–780. doi:10.1200/JCO.2003.02.053
49. de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032–2035. doi:10.1038/sj.leu.2403538
50. Testi AM, Attarbaschi A, Valsecchi MG, et al. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. Eur J Cancer. 2019;122:61–71. doi:10.1016/j.ejca.2019.09.004
51. Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;2018(1):137–145. doi:10.1182/asheducation2018-1.137
52. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res. 2004;10(16):5353–5341. doi:10.1158/1078-0432.Ccr-04-0222
53. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009–2017. doi:10.1016/S0140-6736(10)62002-8
54. Frandsen TL, Heyman M, Abrahamsson J, et al. Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. Eur J Cancer. 2014;50(2):251–259. doi:10.1016/j.ejca.2013.09.027
55. Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231–e239. doi:10.1016/S1470-2153(16)00305-3
56. Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade $\geq$3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials. Leuk Lymphoma. 2018;59(7):1624–1633. doi:10.1080/10428194.2017.1397658
57. Rathod S, Ramsey M, Relling MV, Finkelstein FD, Fernandez CA. Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRII. Haematologica. 2019;104(2):319–329. doi:10.3334/haematol.2018.199448
58. Pieters R, Hunger SP, Boos I, et al. L-asparaginase treatment in acute lymphoblastic leukaemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238–249. doi:10.1002/cncr.25489
59. Strulup M, Corradini N, Audrain M, et al. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukaemia. Leuk Lymphoma. 2010;51(8):1464–1472. doi:10.3109/104281910.2010.94316
60. Zalewska-Szewczyк B, Gach A, Wyka K, Bodalski J, Mlynarski W. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009;9(2):113–116. doi:10.1007/s10238-008-0026-9
61. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(7):1525–1532. doi:10.1200/JCO.2000.18.7.1525
62. Müller H-J, Beier R, Lönig L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001;114(4):794–799. doi:10.1046/j.1365-2410.2001.03009.x
63. Henriksen LT, Harila-Saari A, Ruud E, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;62(3):427–433. doi:10.1002/pbc.25319
64. Hofeldt SG, Wethers BO, Tulstrup M, et al. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008. Br J Haematol. 2019;184(3):405–417. doi:10.1111/bjh.15660
65. Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEG-asparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2066–2033. doi:10.1182/blood-2013-10-35347
66. Kloos RQ, Pieters R, Escherich G, van der Sluis IM. Allergic-like reactions to asparaginase: atypical allergies without asparaginase inactivation. Pediatr Blood Cancer. 2016;63(11):1928–1934. doi:10.1002/pbc.26123
67. Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children’s Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610–616. doi:10.1097/MPH.0b013e31822d464e
68. Würthwein G, Lanvers-Kaminsky C, Geiss J, et al. Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-Asparaginase in the AIEOP-BFM acute lymphoblastic leukemia 2009 Study. Ther Drug Monit. 2020;42(3):435–444. doi:10.1097/FDM.0000000000000727
100. Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol. 2009;22(1):103–114. doi:10.1016/j.beha.2009.01.003

101. Grace RF, Dahlberg SE, Neuberger D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–459. doi:10.1111/j.1365-2141.2010.08524.x

102. Klaassen ILM, Lauw MN, Fiocco M, et al. Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis. Res Pract Thromb Haemost. 2019;3(2):234–241. doi:10.1002/rth2.12182

103. Mogensen SS, Harila-Saari A, Mäkitie O, et al. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(10):e27300. doi:10.1002/pbc.27300

104. Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia. 2008;22(2):308–312. doi:10.1038/sj.leu.2405032

105. Liu C, Janke LJ, Kawedia JD, et al. Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse model. PLoS One. 2016;11(3):e0151433. doi:10.1371/journal.pone.0151433

106. Te Winkel ML, Appel IM, Pieters R, van den Heuvel-eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica. 2008;93(10):1570–1574. doi:10.3324/haematol.12956

107. Liu C, Kawedia J, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26(11):2303–2309. doi:10.1038/leu.2012.102

108. Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG-Asparaginase to reduce Asparaginase-associated toxicities: a NOPHO ALL2008 Randomized Study. J Clin Oncol. 2019;37(19):1638–1646. doi:10.1200/jco.2018.01877

109. Mogensen SS, Schmiegelow K, Grell K, et al. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017;102(5):e175–e178. doi:10.3324/haematol.2016.160507

110. Mattano LA, Devidas M, Friedmann AM, et al. Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): a report from the Children’s Oncology Group (COG) study AALL0331. J Clin Oncol. 2013;31(15_suppl):10002. doi:10.1200/jco.2013.31.15_suppl.10002

Blood and Lymphatic Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.